Tianjin Pharmaceutical da Ren Tang Group Ltd 2024 AR2
The report outlines the financial and operational performance of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited for the fiscal year 2024. The company achieved a net profit attributable to shareholders of RMB 2.23 billion, representing a 126% year-on-year increase, largely driven by the disposal of its 13% stake in Sino-American Tianjin SmithKline Pharmaceutical. Da Ren Tang Group advanced its brand building through five key projects, including the 'Roots-Seeking Journey' and hosting the 11th Chinese Herbal Medicine Base Co-Building and Sharing Exchange Conference. Additionally, the company optimized its health technology division, registered 229 trademarks abroad, and made significant progress in digital intelligence, with five enterprises passing evaluations for digital workshops in Tianjin.
Company: Tianjin Pharmaceutical da Ren Tang Group Ltd
Sector: Manufacturing
Country: China
Year: 2024
Type: AR2
Pages: 192
Back to company
Tianjin Pharmaceutical da Ren Tang Group Ltd
Annual Report
The report outlines the financial and operational performance of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited for the fiscal year 2024. The company achieved a net profit attributable to shareholders of RMB 2.23 billion, representing a 126% year-on-year increase, largely driven by the disposal of its 13% stake in Sino-American Tianjin SmithKline Pharmaceutical. Da Ren Tang Group advanced its brand building through five key projects, including the 'Roots-Seeking Journey' and hosting the 11th Chinese Herbal Medicine Base Co-Building and Sharing Exchange Conference. Additionally, the company optimized its health technology division, registered 229 trademarks abroad, and made significant progress in digital intelligence, with five enterprises passing evaluations for digital workshops in Tianjin.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available